Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose doctors expect them to live for at least 3 more months
- People who have measurable signs of myeloma that meet specific international measurement standards (confirm with trial site)
- People who have already received at least two separate rounds of treatment for myeloma
- People whose myeloma came back, did not respond well enough, or got worse after their most recent treatment
- People whose myeloma cells test positive for a protein called BCMA
- People who are considered fairly well and active, with little or no limitation in daily activities, based on a standard health scoring system (confirm with trial site)
- People whose liver, kidneys, blood clotting, bone marrow, and lungs are all functioning at an acceptable level
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People who have a history of other types of cancer
- People who have an active autoimmune disease that currently requires immune-suppressing treatment
- People who have previously had a stem cell transplant using cells from another person
- People who have previously received CAR-T cell therapy or any other treatment involving genetically modified T cells
- People who have previously received any treatment that specifically targeted the BCMA protein
- People who have a serious heart or cardiovascular condition
- People who currently have an active infection
- People who test positive on certain virus-related blood tests (confirm with trial site)
- People who have significant diseases or changes affecting the brain or nervous system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ping Li, PhD, 13564181131
Phone: 13564181131
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
DLT; AEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.